0
Lung Cancer |

Pleuropulmonary Angiosarcoma Presenting as Bilateral Hemothoraces and Hemoptysis

Sindhuja Marupudi, MD; Maria Carrillo, MD; Dean Meadows, MD
Author and Funding Information

Saint Agnes Hospital, Baltimore, MD


Chest. 2013;144(4_MeetingAbstracts):617A. doi:10.1378/chest.1692603
Text Size: A A A
Published online

Abstract

SESSION TITLE: Cancer Cases I

SESSION TYPE: Medical Student/Resident Case Report

PRESENTED ON: Sunday, October 27, 2013 at 07:30 AM - 08:30 AM

INTRODUCTION: Pleuropulmonary angiosarcoma (PAS) is a very rare highly malignant tumor. Tumors of the pleura, either primary or secondary in origin can be differentiated by immunohistochemistry. Accurate diagnosis is important for treatment and prognosis.

CASE PRESENTATION: A 67 year old African American nonsmoker female with history of goiter and childhood asbestos exposure presented with right upper abdominal pain, neck swelling and shortness of breath for 1 week duration. CT chest showed calcified mass in left lobe of thyroid, right upper lobe pleural based mass, bilateral upper lobe pulmonary nodules, calcified lymph nodes and bilateral large pleural effusions. Ultrasound of the thyroid showed multinodular goiter, negative for color Doppler. She was intubated for hypoxic respiratory failure. Bilateral chest tubes drained 1500ml of blood. Video-assisted thoracoscopy (VATS) showed multiple pleural nodules and dark blood stained pleura. Immunomarkers were negative for thyroid, lung, breast, colon, kidney and ovary. Preliminary biopsy report suggested either mesothelioma or adenocarcinoma of occult primary (AOP). Clinical course was complicated by heparin induced thrombocytopenia. Unfortunately patient passed away 2 weeks after presentation. Final pathology report showed poorly differentiated epithelioid angiosarcoma with no hemolymphoid differentiation.

DISCUSSION: PAS is a very rare sarcoma, (<0.1/100000/year). It presents as pleural thickening, pulmonary mass and hemorrhagic effusion. It is prevalent in Caucasians (65-85%) and men between the ages of 34-85. Risk factors are asbestos exposure, prior radiation and smoking. Mesothelioma, AOP and PAS look alike clinically, radiologically and histologically. The key feature is poorly differentiated cells lining irregular sized vascular channels. Immunomarkers are diagnostic. PAS is positive for vascular markers, Factor 8, CD31 and vimentin. Presence of benign mesothelial cells positive for calretinin, WT1, mesothelin and D2-40, as in our case confounds the diagnosis. PAS is a very difficult tumor to treat. For a solitary mass, surgery and radiation is preferred. Review of the literature showed, for metastatic disease, either monotherapy with Adriamycin, Paclitaxel, Doxorubicin or combination therapy with Mesna, Adriamycin and Ifosfamide can be tried. In PAS maximum survival is 6 months. In mesothelioma patients who complete trimodality therapy, median survival is 29 months. Based on the molecular studies and chemotherapy sensitivity, survival rate varies in AOP.

CONCLUSIONS: Pulmonary angiosarcoma is a rare tumor of vascular origin. In our case, the patient presented with bilateral hemorrhagic pleural effusions, pulmonary nodules and pleural mass, which rapidly proved fatal. Finding the origin of the tumor is facilitated by Immunomarkers. We have only few chemotherapy options and prognosis is dismal.

Reference #1: Primary pleural epithelioid angiosarcoma. A case report and review of literature. E.Dainese etal.

DISCLOSURE: The following authors have nothing to disclose: Sindhuja Marupudi, Maria Carrillo, Dean Meadows

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543